Pharmafile Logo

Opko

- PMLiVE

Pfizer’s Prevnar-13 successor takes aim at Merck rival

Rivals look to broaden coverage across strains

- PMLiVE

Pfizer abandons antibody for Duchenne

Latest to fail in myostatin inhibitor class

- PMLiVE

Novo Nordisk and Evotec inks drug development deal

Will develop drugs for obesity and diabetes

- PMLiVE

Novo’s oral diabetes drug hits the mark again

The drug proves effective in reducing blood sugar in diabetes patients with renal impairment

- PMLiVE

Novo spends $800m to buy biotech and ‘glucose responsive insulin’ tech

Ziylo could help it stay ahead in key insulin franchise

- PMLiVE

Pfizer signs mRNA flu vaccine deal with BioNTech

Pharma giant will take on development and commercial responsibility for candidates

- PMLiVE

Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

Firm relying on launch success in pressured US market

- PMLiVE

Pfizer CEO reckons rebates will disappear, and that’s a positive

The move also has the support of FDA Commissioner Scott Gottlieb

- PMLiVE

Novartis follows Pfizer and freezes US prices this year

And still expects revenues to come in at the high end of expectations for 2018

- PMLiVE

Pfizer enters late-stage haemophilia B gene therapy trial

Race is on to free patients of regular injections

- PMLiVE

Pfizer builds gap between pharma and consumer health units

Its consumer health division will become a standalone unit after lack of buyer interest

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links